AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
18.8 C
New York
Tuesday, September 8, 2026

Tag: response

newssourceFORcompanyinformationcontent1releasesmarket

Beyond IT: Digital Transformation Market Size Set to Hit US$4,617.78 billion by 2030 at 27.6% CAGR, Says The Research Insights

CHICAGO, June 13, 2025 /PRNewswire/ -- The Global Digital Transformation Market size is projected to be valued at USD 1,070.43 billion in 2024 and reach USD 4,617.78...

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

Steer-by-Wire Market Grows as Automakers Embrace Digital Steering for EVs and Smart Mobility | Valuates Reports

BANGALORE, India, June 13, 2025 /PRNewswire/ -- Steer By Wire Market is Segmented by Type (EPS, SBW), by Application (Commercial Vehicle, Passenger Car): Global Opportunity Analysis...

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

Findell Capital Provides Facts in Response to Oportun’s Misleading Narrative

Highlights that the Improvement in the Company's OpEx per Loan Was Driven by Findell's Advocacy and its Identified Director Appointments – Not by Management...

Bridger Aerospace Shares Insights on Executive Order to Reshape Wildland Firefighting

Significant Increase to DOI’s Fiscal 2026 Budget Request further Prioritizes Preparedness and Rapid Response 
Significant Increase to DOI’s Fiscal 2026 Budget Request further Prioritizes Preparedness and Rapid Response

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResponse

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers